Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Decrease in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 44,387 shares, a decline of 49.2% from the February 12th total of 87,354 shares. Based on an average trading volume of 2,970,184 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 2,970,184 shares, the short-interest ratio is currently 0.0 days.

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $11.20 on Friday. The firm’s 50 day moving average is $12.47 and its 200-day moving average is $9.99. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $44.02 billion, a PE ratio of -10.09 and a beta of 0.69. Bayer Aktiengesellschaft has a 12-month low of $5.30 and a 12-month high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. The business had revenue of $13.24 billion during the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. Equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. DZ Bank lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 23rd. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Finally, Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.